Diseases [C] - Skin and Connective Tissue Diseases [C17] Clinical Trials

390 clinical trials for Diseases [C] - Skin and Connective Tissue Diseases [C17] across international registries, including 36 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• First in human, Phase 1a/1b Study of KM-023 in healthy volunteers and Olmsted syndrome patients — RECRUITING · PHASE1
• A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors — RECRUITING · PHASE2
• Double-blind placebo-controlled clinical trial (Phase 1b/2a) to evaluate safety and efficacy of IM-250 administration in patients with recurrent genital herpes. — RECRUITING · PHASE2
• A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment - EFC17599 / AQUA — RECRUITING · PHASE3
• A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment. — RECRUITING · PHASE2
• A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE) — RECRUITING · PHASE3
• A multicentre, intra-patient randomised controlled Phase III study to confirm the efficacy and safety of denovoSkin™, a bilayer engineered collagen-based skin graft composed of autologous fibroblasts and keratinocytes, for the treatment of patients with deep partial and full-thickness burns — RECRUITING · PHASE3
• A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib — RECRUITING · PHASE3
• Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta — RECRUITING · PHASE3
• A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT) — RECRUITING · PHASE4
• A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (age 2 to <12 years) and infants (age 6 months to <2 years) with moderate-to-severe atopic dermatitis. The trial is randomized, double-blind, placebo-controlled, and parallel-group for children (age 2 to <12 years) and open label and single-group for infants (age 6 months to <2 years) — RECRUITING · PHASE3
• An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy and Durability of Response to ESK-001 (ONWARD3) — RECRUITING · PHASE3
• B7451031 - A Phase 3, Multicenter, Long-Term, Open-Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis — RECRUITING · PHASE3
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care — RECRUITING · PHASE3
• Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial) — RECRUITING · PHASE1
• A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the treatment of partial deep dermal and full thickness burns in children in comparison to autologous split-thickness skin grafts (STSG) (BC) — RECRUITING · PHASE2
• A clinical study to assess if a new investigational medicinal product called JJP-1212 is safe, tolerable and able to induce a specific immune response in humans — RECRUITING · PHASE1
• The effects of belimumab on synovial inflammation and composition of lymph nodes in SLE patients — RECRUITING · PHASE4
• A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 Versus Placebo Administered Subcutaneously in Pediatric (2 to < 12 years of age) Participants with Hypophosphatasia Who Have Not Received Previous Treatment with Asfotase Alfa — RECRUITING · PHASE3
• A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa — RECRUITING · PHASE2
• An Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis with Moderate-to-Severe Pruritus (KOR-PED-202) — RECRUITING · PHASE2
• Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU) — RECRUITING · PHASE2
• MERCURE study: MEthotrexate in ReCurrent dVIN — RECRUITING · PHASE4
• A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma — RECRUITING · PHASE3
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis — RECRUITING · PHASE3
• Multicenter phase 1b/II trial testing neoadjuvant intradermal Ipilimumab and Nivolumab in high risk stage II melanoma –MARIANE — RECRUITING · PHASE2
• A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma — RECRUITING · PHASE1
• Open-label, randomized, assessor-blinded, efficacy, safety, tolerability, and pharmacokinetics study of subcutaneous risankizumab with an adalimumab reference arm in children with active juvenile psoriatic arthritis — RECRUITING · PHASE3
• A phase 2a multicentric study of TAR-0520 gel in EGFR inhibitor-induced folliculitis — RECRUITING · PHASE2
• A first-in-human, open-label, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease. — RECRUITING · PHASE1
• A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB-UVB Light Alone in the Treatment of Vitiligo — RECRUITING · PHASE3
• A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product — RECRUITING · PHASE1
• An exploratory, multicenter, randomized, open-label with blind evaluation, active-controlled study to evaluate the safety and efficacy of Keramod® (imiquimod 50 mg/g, Gel) compared with Aldara® (imiquimod 50 mg/g, Cream) for the treatment of actinic keratosis in adults. — RECRUITING · PHASE2
• Satisfaction study of split doses botulinum toxin with double frequency — RECRUITING · PHASE3
• Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector — RECRUITING · PHASE2
• EFFECT OF DEXAMETASONE ON LOWER LIMB EDEMA IN PATIENTS UNDERTAKEN FOR TOTAL HIP ARTHROPLASTY — RECRUITING · PHASE4
• A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc) — NOT_YET_RECRUITING · PHASE3
• A phase 2B, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of Rezpegaldesleukin in the treatment of severe to very severe alopecia areata in adult patients (Rezolve AA) — TERMINATED · PHASE2
• A phase 2a exploratory study of TAR-0520 gel in prevention of Hand and Foot Syndrome — NOT_YET_RECRUITING · PHASE2
• IJAMP-Trial — NOT_YET_RECRUITING · PHASE4
• A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD) — TERMINATED · PHASE3
• A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD328 in adult subjects with moderate to severe hidradenitis suppurativa — TERMINATED · PHASE2
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS — TERMINATED · PHASE2
• A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the safety of EscharEx in debridement of Venous Leg Ulcers (VALUE) — TERMINATED · PHASE3
• APG777-202 - A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777 — TERMINATED · PHASE2
• An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma — NOT_YET_RECRUITING · PHASE2
• A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period — TERMINATED · PHASE2
• A long-term safety and efficacy study of N-Acetyl-GED-0507-34-LEVO gel 5%, in subjects with acne vulgaris (GEDACNE-LT) — TERMINATED · PHASE3
• A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 with Cosentyx in Patients with Moderate to Severe Plaque Psoriasis — TERMINATED · PHASE3
• A Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group 52-week extension study to evaluate the treatment response and safety of two amlitelimab dose regimens administered by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis — TERMINATED · PHASE3

Refine this search